Author Archives: Charles Moore

New artificial intelligence (AI) research conducted at McGill University in Canada suggests that doctors may soon have the tools to predict an individual’s likelihood of developing dementia several years before the onset of symptoms. Such extended prognostic capability would give future dementia patients and their families more time to plan strategies…

A student-led team of researchers at Washington University School of Medicine (WUSM) in St. Louis, Missouri, has developed an online app designed to streamline the process of Alzheimer’s disease diagnosis. It provides physicians with more information about patients before they are evaluated in person, enabling physicians to assess and assist patients…

The National Institutes of Health has awarded the University of California at Davis a multiyear grant of nearly $14.7 million to pinpoint the reasons why Latinos have higher rates of dementia than other American ethnic groups. Nine other universities will take part in the UC Davis-led study. Researchers will…

The Mediterranean diet is widely associated with an array of health benefits including lower incidence of dementia and Alzheimer’s disease (AD). Researchers at Temple University’s Lewis Katz School of Medicine (LKSOM), in Philadelphia, have found that one major component of the Mediterranean diet in…

People with Alzheimer’s disease who live alone in their home are likely to receive a lower standard of diagnosis and treatment than those who live with others — even though their numbers are growing, according to a Swedish study published in the Journal of Alzheimer’s Disease. The study, “Living Alone with Alzheimer’s Disease: Data…

The U.S. Congress last week authorized an additional 40 percent in funds for Alzheimer’s disease (AD) research, boosting the fiscal 2017 total by $400 million to nearly $1.4 billion as part of a $2 billion year-over-year increase for the National Institutes of Health (NIH). The final package won praise from the nonprofit…

Oryzon Genomics is receiving $300,000 from the Alzheimer’s Drug Discovery Foundation to continue developing its Alzheimer’s treatment ORY-2001. In exchange, the foundation, which has been a longtime partner of Oryzon, will receive shares of the company’s stock. Oryzon develops epigenetics therapies, which regulate genome function without affecting the makeup of genes…

The Alzheimer’s Foundation of America (AFA), which represents more than 2,600 member organizations nationwide, testified March 29 at a Senate hearing in Washington that discussed issues related to cognitive decline. The AFA’s brief to the Senate Special Committee on Aging described the state of Alzheimer’s disease and its impact on…

Medical marijuana’s potential as an effective treatment for the progression of Alzheimer’s disease is high on the list of discussion topics as more than 300 medical practitioners, attorneys and industry experts gather for the second annual South Florida Medical Cannabis Symposium to be held at the Westin Fort…

The non-profit UsAgainstAlzheimers organization has started a program that has a key goal of addressing African-American and Latino underrepresentation in neurological research. Recognizing that Alzheimers disproportionately affects people of color, another goal of the program will be to build a national network of doctors, researchers, patients, caregivers and others involved…